Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/PER-059-02
PER-059-02Completed未知

MULTICENTRIC, DOUBLE-BLIND, FACTORIAL STUDY CONTROLLED WITH PLACEBO AND RANDOMIZED TO EVALUATE EFFICACY AND SAFETY IN THE ALTERATION OF LIPIDS OF THE EZETIMIBE / SIMVASTATIN MIXED TABLET IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

MERCK SHARP & DOHME PERU S.R.L.,0 sites0 target enrollmentStarted: September 4, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •a. Men or women> 18 and <80 years of age.
  • •b. People willing to make a regimen of Therapeutic Changes of
  • •Lifestyle (TLC) of the NCEP or a similar diet of cholesterol reduction during the course of the study.

Exclusion Criteria

  • •a. Weight <50% of the ideal body weight according to the Weight and Height Tables
  • •Metropolitans of 1983 (Appendix 2) or weighing <100 pounds (45 kg).
  • •b. Hypersensitivity to HMG.-CoA reductase inhibitors.
  • •c. Patients who already receive lipid reduction therapy in which the
  • •suspension of therapy for the course of the study would be inappropriate to
  • •the investigator´s judgment.
  • •d. Alcohol consumption> 14 drinks per week.
  • •e. Pregnant women or breastfeeding

Investigators

Sponsor
MERCK SHARP & DOHME PERU S.R.L.,

Similar Trials

Completed
Not Applicable
Montelukast Asthmatic Smoker Study-J459 Asthma, unspecifiedAsthma, unspecifiedJ459
PER-008-06MERCK SHARP & DOHME PERU S.R.L.,
Completed
Not Applicable
A DOUBLE-BLIND, RANDOMIZED, MULTI-CENTRAL STUDY OF 3 PERIODS, CROSSED TO EVALUATE THE EFFECTS OF A SINGLE DOSE OF MONTELUKAST COMPARED TO THE PLACEBO AND SALMETEROL IN BRONCHOCONSTRICTION INDUCED BY EXERCISE-J45J45
PER-059-05MERCK & CO.INC.,
Completed
Not Applicable
MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, IN PARALLEL GROUPS, WITH ACTIVE CONTROL, OF 24 WEEKS OF DURATION, TO EVALUATE THE EFFICACY OF THE COMBINATION VALSARTAN / HYDROCHLOROTHYAZIDE VERSUS AMLODIPINE ON THE SYSTOLIC ARTERIAL PRESSURE IN PATIENTS WITH MODERATE HYPERTENSION WITH RISK FACTORS AND / OR CARDIOVASCULAR CONCOMYANT DISEASE-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10
PER-010-03OVARTIS BIOSCIENSES PERU S.A.,
Completed
Not Applicable
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE CLINICAL EFFECTS OF MONTELUKAST INTRAVENOUS WITH PLACEBO IN PEDIATRIC PATIENTS (BETWEEN 6 AND 14 YEARS OLD) WHO SUFFER FROM ACUTE ASTHMA-J459 Asthma, unspecifiedAsthma, unspecifiedJ459
PER-028-05MERCK & CO.INC.,
Completed
Not Applicable
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE CLINICAL EFFECTS OF MONTELUKAST INTRAVENOUS WITH PLACEBO IN PATIENTS WITH ACUTE ASTHMA
PER-034-04MERCK & CO.INC.,